EUCTR2005-005170-80-IT进行中（未招募）不适用
A Randomized, Multicentre Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of ProxiniumTM Plus Best Supportive Care Versus Best Supportive Care Alone in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck Who Have Received at Least One Anti-cancer Treatment Regimen for Advanced Disease - ND
VIVENTIA BIOETICH INC0 个研究点目标入组 292 人开始时间: 2007年5月18日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 292
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must have advanced Ep-CAM positive SCCHN, have received at least 1 anti-cancer treatment regimen for their advanced disease and not be eligible for curative surgery or curative radiotherapy. Patients must have a life expectancy of at least 12 weeks, an ECOG performance status of 0, 1, 2 or 3 and have tumours that are suitable for intratumoural injection.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients will not be eligible for the study if they have clinically significant distant metastases or hepatic or renal disease.
研究者
相似试验
进行中（未招募）
不适用
A RANDOMIZED, MULTICENTRE THERAPEUTIC CONFIRMATORY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PROXINIUM™ PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN PATIENTS WITH ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK WHO HAVE RECEIVED AT LEAST ONE ANTI-CANCER TREATMENT REGIMEN FOR ADVANCED DISEASEAdvanced Ep-CAM Positive Squamous Cell Carcinoma of the Head and NeckEUCTR2005-005170-80-GBViventia Biotech Inc.292
进行中（未招募）
不适用
A RANDOMIZED, MULTICENTRE THERAPEUTIC CONFIRMATORY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PROXINIUM™ PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN PATIENTS WITH ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK WHO HAVE RECEIVED AT LEAST ONE ANTI-CANCER TREATMENT REGIMEN FOR ADVANCED DISEASEEUCTR2005-005170-80-HUViventia Biotech Inc.292
进行中（未招募）
不适用
A RANDOMIZED, MULTICENTRE THERAPEUTIC CONFIRMATORY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PROXINIUM™ PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN PATIENTS WITH ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK WHO HAVE RECEIVED AT LEAST ONE ANTI-CANCER TREATMENT REGIMEN FOR ADVANCED DISEASEAdvanced Ep-CAM Positive Squamous Cell Carcinoma of the Head and NeckEUCTR2005-005170-80-FRViventia Biotech Inc.292
进行中（未招募）
1 期
A RANDOMIZED, MULTICENTRE THERAPEUTIC CONFIRMATORY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PROXINIUM™ PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN PATIENTS WITH ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK WHO HAVE RECEIVED AT LEAST ONE ANTI-CANCER TREATMENT REGIMEN FOR ADVANCED DISEASEAdvanced Ep-CAM Positive Squamous Cell Carcinoma of the Head and NeckEUCTR2005-005170-80-SKViventia Biotech Inc.292
进行中（未招募）
不适用
A RANDOMIZED, MULTICENTRE THERAPEUTIC CONFIRMATORY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PROXINIUM™ PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN PATIENTS WITH ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK WHO HAVE RECEIVED AT LEAST ONE ANTI-CANCER TREATMENT REGIMEN FOR ADVANCED DISEASEAdvanced Ep-CAM Positive Squamous Cell Carcinoma of the Head and NeckEUCTR2005-005170-80-DEViventia Biotech Inc.292